Article -> Article Details
|Title||Oral Mucositis Market In-Depth Analysis on Size, Cost Structure and Key Players 2027|
|Category||Fitness Health --> Health Articles|
|Meta Keywords||Oral Mucositis Market|
The number of the cancer patients are increasing, and the chemotherapy is used in most of the severe cases. The aggressive use of chemotherapy is leading to develop mouth ulcers and other oral problem as the side effect of the high dose drugs. Mucositis can have a devastating effect on a person’s nutritional status because the oral pain related with the condition often prevents individuals from eating solid food, and sometimes even from swallowing.
The market for the oral mucositis is a mouth problem which happens because of the drugs taken through the chemotherapy and radiotherapy. Sometimes it may happen because of the hematopoietic stem cell transplantation. The oral mucositis market is problem of ulcers and infection which can happen also because of eating habits, oral unhygienic conditions and many more such problems.
Most patients undergo chemotherapy on an outpatient basis and are admitted to the hospital if they develop fever and neutropenia, obvious infection, or some other complication. Yet, oral complications, when they arise in either the inpatient setting or the outpatient setting, are similar. The rapid expansion of health care is providing impetus to the small but growing field of oral mucositis treatment.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1531
Izun Pharmaceutical Ltd (US), Shoreline Pharmaceuticals Inc. (USA), Himalaya (India), AMAG Pharmaceuticals Inc. (USA), Kinnear Pharmaceuticals (US), Celleutix Corporation (USA), Soligenix Inc. (US), Oragenics (US) are some of the prominent players at the forefront of competition in the Global Oral Mucositis Market and are profiled in MRFR Analysis.
May 2017 Soligenix Inc., company has got FDA clearance for protocol pivotal phase 3 clinical trial for the SGX942 which will be used for the treatment of oral mucositis, head, and neck cancer. The drug has received approval marketing support from the US and European Union.
November 2016 Oragenics, FDA has approved fast track designation to AG013, which will be used for the Oral Mucositis. Oragenics has filed an Investigational New Drug (IND) update and initiate a Phase 2 study with AG013 in the United States and Europe.
Izun Pharmaceutical Ltd, is a biopharmaceutical company having product portfolio of powerful non-steroidal topical oral anti-inflammatory therapies with superior efficacy and safety to current periodontal treatments. Company manufactures product form naturally derived pharmaceutical actives for the treatment of oral disease with inflammatory components. Company has breakthrough product for treatment of peri-implantitis that affects the dental implants. The product is known as Perio Patch which affects the mucositis after implantation.
AMAG Pharmaceuticals, has product Mu Gard which is Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis and the other oral wounds.
Cellutix Corporation, company has fasten up the process of phase two clinical trial for the Brilacidin which will used to treat oral mucositis. In July 2016 the company received positive feedback for the drug after it was used on a patient and in phase two proof of concept.
Himalaya, the company is Indian based company producing all its products from herbal base. The company has product Hiora-SG which a gel use to apply on the mouth ulcers. The gel also controls the body’s immune response and prevents the recurrence of mouth ulcers. The product does not show any side effects and is highly recommended in Indian market.
The treatment for the oral mucositis is more established in the America, owing to the healthcare services and facilities are much better and advanced. Moreover, globally the incidence and death rate due to the oral cancer is increasing. The number of the cases are found more in the men than women.
Get Access Full Report @ https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531
The reason for oral cancer differs for the different regions based on the risk and available and accessibility of the health care services. The 90% of the oral cancers are detected due to the high consumptions of the tobacco and the smoking habit. The 40% patients undergoing the chemotherapy show the oral mucositis. The European market for oral mucositis is expected to grow at substantial during forecast period and Asia-Pacific projected to be fastest growing during 2017 - 2023.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312